The term ‘pharmacogenomics’ describes how common gene variants influence drug metabolism and response.
There are common variants in cytochrome P450 enzymes (CYPs) and drug receptors that influence the rate of metabolism of many commonly prescribed drugs. Individuals are typically classified as ‘poor’, ‘intermediate’, ‘extensive’ or ‘ultrarapid’ metabolisers depending on their CYP variants. Poor and ultrarapid metabolisers may require different dosages, or be more susceptible to adverse drug effects.3
Table 1 provides examples of drugs that may be affected by common gene variants.
Examples of drugs affected by common gene variants1